Gene expression-based prediction of neodjuvant chemotherapy response in early breast cancer

Download

Prospective, non-comparative Phase II multicenter trial (EXPRESSION EudraCT: 2008-006381-29) where the patients received three 3-week cycles of docetaxel (100 mg/m2) followed by three 3-week cycles of 5-fluorouracil (500 mg/m2), epirubicin (100 mg/m2), and cyclophosphamide (500 mg/m2) (FEC). The primary end point was the identification of a gene expression signature predictive of pathological complete response (pCR). In this trial, pCR was defined as absence of invasive or non-invasive cancer in the breast. External validation of the predictive performance was performed using publicly available data.

Cancer Type: Breast Cancer

GPL: 570

Number of Genes with Data: 978

Number Observations: 91

Number Outputs: 4

Imbalanced Ratio: 0.516666667

Default Task: Classification